Drug – bio-affecting and body treating compositions – Whole live micro-organism – cell – or virus containing – Genetically modified micro-organism – cell – or virus
Reexamination Certificate
2005-10-18
2005-10-18
Guzo, David (Department: 1636)
Drug, bio-affecting and body treating compositions
Whole live micro-organism, cell, or virus containing
Genetically modified micro-organism, cell, or virus
C435S320100, C435S456000, C536S023100, C536S023400
Reexamination Certificate
active
06955808
ABSTRACT:
The present invention describes recombinant adenoviral vectors modified by incorporating targeting ligands or label into viral capsid or structural proteins. In one embodiment, single-chain antibody was introduced into the minor capsid proteins pIIIa or pIX so that the adenoviral vector can be targeted to a particular cell type. In another embodiment, there is provided a noninvasive imaging strategy useful for monitoring the replication and spread of conditionally replicative adenoviral vectors. Viral structural proteins such as pIX capsid protein, core proteins mu, V and VII were expressed as fusion protein with a fluorescent label. Once incorporated into the virions, detection of the structural fusion protein label would indicate the localization of the disseminated viral progeny. The detected fluorescent signals also closely correlate with the level of viral replication and progeny production.
REFERENCES:
patent: 5723287 (1998-03-01), Russell et al.
patent: 5846782 (1998-12-01), Wickham et al.
patent: 5871727 (1999-02-01), Curiel
patent: 6740525 (2004-05-01), Roelvink et al.
patent: 99/36545 (1999-07-01), None
patent: WO 97/20051 (1997-06-01), None
patent: WO 99/36545 (1999-07-01), None
Boudin et al. Human adenovirus type 2 protein IIIa. Virology 101:144-156, 1980.
Alemany et al. CAR-binding ablation does not change biodistribution and toxicity of adenoviral vectors. Gene therapy 8:1347-1353, 2001.
Martin et al. Simultaneous CAR- and alphav Integrin-binding ablation fails to reduce Ad5 liver tropism. Mol. Therapy 8:485-494, 2003.
Akalu et al. The subgenus-specific C-terminal region of protein IX is located on the surface of the adenoviral capsid. J. Virol. 73:6182-6187, 1999.
Wickham et al. Increased in vitro and in vivo gene transfer by adenovirus vectors containing chimeric fiber proteins. J. Virol. 71:8221-8229, 1997.
Weissleder & Ntziachristos, “Shedding light onto live molecular targets,” Nature Medicine 9(1):123-128 (2003).
Curiel, D. et al., “Strategies to Adapt Adenoviral Vectors for Targeted Delivery,” Ann. NY Acad. Sci., 886: 158-71, 1999.
Dang et al., “Gene Therapy and Translational Cancer Research,” Clinical Cancer Research, 5: 471-74, 1999.
Deonarain, “Ligand-Targeted Receptor-Mediated Vectors for Gene Delivery,” Exp. Opin. Ther. Patents, 8(1):53-69, 1998.
Douglas, J. et al., “A system for the propagation of adenoviral vectors with genetically modified receptor specificities,” Nat. Biotechnl., 17:470-75.
Krasnykh, V. et al., “Generation of Recombinant Vectors with Modified Fibers for Altering Viral Tropism,” J. Virol., 70:6839-46, 1996.
Manuel Rosa-Calatrava et al., “Functional Analysis of Adenovirus Protein IX Identifies Domains Involved in Capsid Stability, Transcriptional Activity, and Nuclear Reorganization,” J. Virol., 75:7131-41, 2001.
Meng et al., “Tumor Suppressor Genes as Targets for Cancer Gene Therapy,” Gene Therapy of Cancer, 3-20, 1999.
Miller et al., “Targeted Vectors for Gene Therapy,” FASEB J., 9:190-99, 1995.
Ngo et al., “Computational Complexity, Protein Stucture Prediction, and the Levinthal Paradox,” In: Protein Folding Problem and Teritary, Stucture Prediction (Merz et al., eds.), Birkhauser, Boston, pp. 419-494, 1994.
Peng et al., “Viral Vector Targeting,” Current Opinion in Biotechnology, 10: 454-57, 1999.
Rudinger, “Characteristics of the Amino Acids as Components of a Peptide Hormone Sequence,” In: Peptide Hormones (Parsons, J.A., ed.), University Park Press, Baltimore, pp. 1-7, 1996.
Verma, et al., “Gene Therapy—Promises, Problems and Prospects,” Nature, 389: 239-42, 1997.
Wickham, T. et al., “Targeted Adenovirus Gene Transfer to Endothelial and Smooth Muscle Cells by Using Bispecific Antibodies,” J. Virol., 70: 6831-38, 1996.
Wickham, T. et al., “Targeted Adenovirus-Mediated Gene Delivery to T Cells via CD3,” J. Virol., 71: 7663-69, 1997.
Balague C et al., Human papillomavirus E6E7-mediated adenovirus cell killing:selectivity of mutant adenovirus replication in organotypic cultures of human keratinocytes, J. Virol. 75:7602-11 (2001).
Bevis and Glick, Rapidly maturing variants of the Discosoma red fluorescent protein (DsRed), Nat Biotechnol. 20:83-7 (2002).
Bhaumik and Gambhir, Optical imaging of Renilla luciferase reporter gene expression in living mice, Proc Natl Acad Sci USA, 99:377-82 (2002).
Burclo et al., Detecting protein—protein interactions using Revilla luciferase fusion proteins. Biotechniques 33:1044-8, 1050 (2002).
Campbell et al., A monomeric red fluorescent protein, Proc Natl Acad Sci USA, 99:7877-82 (2002).
Chartier et al., Efficient generation of recombinant adenovirus vectors by homologous recombination inEscherichia coli,J. Virol. 70:4805-4810 (1996).
Chaudhuri et al., A noninvasive reporter system to image adenoviral-mediated gene transfer to ovarian cancer xenografts. Gynecol Oncol. 83:432-8 2001).
Chaudhuri et al., Light-based imaging of green fluorescent protein-positive ovarian cancer xenografts during therapy. Gynecol Oncol. 82:581-9 (2001).
Diehn et al., Noninvasive fluorescent imaging reliably estimates biomass in vivo. Biotechniques 33:1250-2, 1254-5 (2002).
Dmitriev et al., Engineering of adenovirus vectors containing heterologous peptide sequences in the C terminus of capsid protein IX. J Virol. 76:6893-9 (2002).
Gross et al., The structure of the chromophore within DsRed, a red fluorescent protein from coral, Proc Natl Acad Sci USA. 97:11990-5 (2000).
Gurskaya et al., GFP-like chromoprotein as a source of far-red fluorescent proteins. FEBS Lett. 507:16-20 (2001).
He et al., A simplified system for generating recombinant adenoviruses, Proc Natl Acad Sci USA, 95:2509-14 (1998).
Hoffman, Visualization of GFP-expressing tumors and metastasis in vivo. Biotechniques 30:1016-22, 1024-6 (2001).
Hyin et al., Fiber-optic monitoring coupled with confocal microscopy for imaging gene expression in vitro and in vivo. J Neurosci Methods 108:91-6 (2001).
Rooney et al., Laser fluorescence bronchoscopy for detection of fluorescent reporter genes in airway epithelia, Gene Ther. 9:1639-44 (2002).
Wang et al., Renilla luciferase-Aequorea GFP (Rue-GFP) fusion protein, a novel dual reporter for real-time imaging of gene expression in cell cultures and in live animals, Mol. Genet Genomics 268:160-8 (2002).
Weissleder and Mahmood, Molecular imaging, Radiology 219: 316-33 (2001).
Yamamoto et al., Infectivity Enhanced, Cyclooxgenase-2 Promoter-Based Conditionally Replicative Adenovirus for Pancreatic Cancer, Gastroenterology, 125(4):1203-18 (2003).
Yang et al., Whole-body optical imaging of green fluorescent protein-expressing tumors and metastases. Proc Natl Acad Sci USA. 97:1206-11 (2000).
Yang et al., Visualizing gene expression by whole-body fluorescence imaging, Proc Natl Acad Sci USA 97:12278-82 (2000).
Yang et al., Direct external imaging of nascent cancer, tumor progression, angiogenesis, and metastasis on internal organs in the fluorescent orthotopic model. Proc Natl Acad Sci USA. 99:3824-9 (2002).
Frommer Lawrence & Haug
Guzo David
Kowalski Thomas J.
Lu Deborah L.
Nguyen Quang
LandOfFree
Capsid-modified recombinant adenovirus and methods of use does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Capsid-modified recombinant adenovirus and methods of use, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Capsid-modified recombinant adenovirus and methods of use will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3490707